Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
SARS-CoV-2 as a superantigen in multisystem inflammatory syndrome in children
Theodore Kouo, Worarat Chaisawangwong
Theodore Kouo, Worarat Chaisawangwong
Published April 12, 2021
Citation Information: J Clin Invest. 2021;131(10):e149327. https://doi.org/10.1172/JCI149327.
View: Text | PDF
Commentary

SARS-CoV-2 as a superantigen in multisystem inflammatory syndrome in children

  • Text
  • PDF
Abstract

Multisystem inflammatory syndrome in children (MIS-C) is a rare but deadly new disease in children that rapidly progresses to hyperinflammation and shock, and can lead to multiple organ failure if unrecognized. It has been found to be temporally associated with the COVID-19 pandemic and is often associated with SARS-CoV-2 exposure in children. In this issue of the JCI, Porritt, Paschold, et al. identify restricted T cell receptor (TCR) β-chain variable domain (Vβ) usage in patients with severe MIS-C, indicating a potential role for SARS-CoV-2 as a superantigen. These findings suggest that a blood test that determines the presence of specific TCRβ variable gene (TRBV) segments may identify patients at risk for severe MIS-C.

Authors

Theodore Kouo, Worarat Chaisawangwong

×

Figure 1

Potential mechanisms for T cell activation in MIS-C.

Options: View larger image (or click on image) Download as PowerPoint
Potential mechanisms for T cell activation in MIS-C.
(A) Superantigen an...
(A) Superantigen and conventional antigen activate T cells to expand in a polyclonal or clonal manner. Because superantigens classically activate T cells by binding to the Vβ region (blue) without interacting with the CDR3 loops (red, green, purple), the expanded polyclonal T cell population demonstrates shared Vβ usage but diversity in CDR3 sequences and lengths. In contrast, T cells activated by conventional antigens depend on interactions of the CDR3 loop with the peptide-MHC complex. Thus, T cells expanded by conventional antigens demonstrate clonal expansion with shared CDR3 loops as well as Vβ usage. The findings in Porritt, Paschold, et al. (9) suggest that superantigens drive T cell expansion in MIS-C. (B) The two-hit model for MIS-C posits that the first hit occurs from nonspecific superantigen activation of a polyclonal T cell population by SARS-CoV-2. The second hit occurs following infection with a second virus, leading to robust reactivation of a previously expanded T cell subgroup from the first hit. This subgroup of T cells may also cross-react with self-antigens, leading to tissue injury.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts